Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. J of Skin. 2024;8(4):s404. doi:10.25251/skin.8.supp.404